164 related articles for article (PubMed ID: 29987129)
1. Creating a comprehensive research strategy for cutaneous neurofibromas.
Blakeley JO; Wolkenstein P; Widemann BC; Lee J; Le LQ; Jackson R; Stathis M; Verma SK
Neurology; 2018 Jul; 91(2 Suppl 1):S1-S4. PubMed ID: 29987129
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous neurofibromas: Current clinical and pathologic issues.
Ortonne N; Wolkenstein P; Blakeley JO; Korf B; Plotkin SR; Riccardi VM; Miller DC; Huson S; Peltonen J; Rosenberg A; Carroll SL; Verma SK; Mautner V; Upadhyaya M; Stemmer-Rachamimov A
Neurology; 2018 Jul; 91(2 Suppl 1):S5-S13. PubMed ID: 29987130
[TBL] [Abstract][Full Text] [Related]
3. The biology of cutaneous neurofibromas: Consensus recommendations for setting research priorities.
Brosseau JP; Pichard DC; Legius EH; Wolkenstein P; Lavker RM; Blakeley JO; Riccardi VM; Verma SK; Brownell I; Le LQ
Neurology; 2018 Jul; 91(2 Suppl 1):S14-S20. PubMed ID: 29987131
[TBL] [Abstract][Full Text] [Related]
4. Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical Trials.
Cannon A; Pichard DC; Wolters PL; Adsit S; Erickson G; Lessing AJ; Li P; Narmore W; Röhl C; Rosser T; Widemann BC; Blakeley JO; Plotkin SR;
Neurology; 2021 Aug; 97(7 Suppl 1):S15-S24. PubMed ID: 34230202
[TBL] [Abstract][Full Text] [Related]
5. Clinical trial design for cutaneous neurofibromas.
Cannon A; Jarnagin K; Korf B; Widemann BC; Casey D; Ko HS; Blakeley JO; Verma SK; Pichard DC
Neurology; 2018 Jul; 91(2 Suppl 1):S31-S37. PubMed ID: 29987133
[TBL] [Abstract][Full Text] [Related]
6. Considerations for development of therapies for cutaneous neurofibroma.
Verma SK; Riccardi VM; Plotkin SR; Weinberg H; Anderson RR; Blakeley JO; Jarnagin K; Lee J
Neurology; 2018 Jul; 91(2 Suppl 1):S21-S30. PubMed ID: 29987132
[TBL] [Abstract][Full Text] [Related]
7. Measuring the Effect of Cutaneous Neurofibromas on Quality of Life in Neurofibromatosis Type 1.
Maguiness S; Berman Y; Rubin N; Dodds M; Plotkin SR; Wong C; Moertel C;
Neurology; 2021 Aug; 97(7 Suppl 1):S25-S31. PubMed ID: 34230204
[TBL] [Abstract][Full Text] [Related]
8. A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials.
Fertitta L; Bergqvist C; Sarin KY; Plotkin SR; Moertel C; Petersen AK; Cannon A; Berman Y; Pichard DC; Röhl C; Lessing A; Brizion B; Peiffer B; Ravaud P; Tran VT; Armand ML; Moryousef S; Ferkal S; Jannic A; Ezzedine K; Wolkenstein P;
Br J Dermatol; 2024 Jan; 190(2):216-225. PubMed ID: 37877514
[TBL] [Abstract][Full Text] [Related]
9. Spatiotemporal Loss of
Chen Z; Mo J; Brosseau JP; Shipman T; Wang Y; Liao CP; Cooper JM; Allaway RJ; Gosline SJC; Guinney J; Carroll TJ; Le LQ
Cancer Discov; 2019 Jan; 9(1):114-129. PubMed ID: 30348677
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous neurofibromas in the genomics era: current understanding and open questions.
Allaway RJ; Gosline SJC; La Rosa S; Knight P; Bakker A; Guinney J; Le LQ
Br J Cancer; 2018 Jun; 118(12):1539-1548. PubMed ID: 29695767
[TBL] [Abstract][Full Text] [Related]
11. Quality of life in neurofibromatosis 1: development and validation of a tool dedicated to cutaneous neurofibromas in adults.
Fertitta L; Bergqvist C; Armand ML; Moryousef S; Ferkal S; Jannic A; Ravaud P; Tran VT; Ezzedine K; Wolkenstein P
J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1359-1366. PubMed ID: 35412677
[TBL] [Abstract][Full Text] [Related]
12. Robust surgical approach for cutaneous neurofibroma in neurofibromatosis type 1.
Chamseddin BH; Hernandez L; Solorzano D; Vega J; Le LQ
JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31038470
[TBL] [Abstract][Full Text] [Related]
13. The evolution and multi-molecular properties of NF1 cutaneous neurofibromas originating from C-fiber sensory endings and terminal Schwann cells at normal sites of sensory terminations in the skin.
Rice FL; Houk G; Wymer JP; Gosline SJC; Guinney J; Wu J; Ratner N; Jankowski MP; La Rosa S; Dockum M; Storey JR; Carroll SL; Albrecht PJ; Riccardi VM
PLoS One; 2019; 14(5):e0216527. PubMed ID: 31107888
[TBL] [Abstract][Full Text] [Related]
14. Target Product Profile for Cutaneous Neurofibromas: Clinical Trials to Prevent, Arrest, or Regress Cutaneous Neurofibromas.
Ly I; Romo CG; Gottesman S; Kelly KM; Kornacki D; York Z; Lee SY; Rhodes SD; Staedtke V; Steensma MR; Blakeley JO; Wolkenstein P
J Invest Dermatol; 2023 Aug; 143(8):1388-1396. PubMed ID: 37294242
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous neurofibromas: patients' medical burden, current management and therapeutic expectations: results from an online European patient community survey.
Guiraud M; Bouroubi A; Beauchamp R; Bocquet A; Grégoire JM; Rauly-Lestienne I; Blanco I; Wolkenstein P; Schmitt AM
Orphanet J Rare Dis; 2019 Dec; 14(1):286. PubMed ID: 31801570
[TBL] [Abstract][Full Text] [Related]
16. Validating Techniques for Measurement of Cutaneous Neurofibromas: Recommendations for Clinical Trials.
Thalheimer RD; Merker VL; Ly KI; Champlain A; Sawaya J; Askenazi NL; Herr HP; Da JLW; Jordan JT; Muzikansky A; Pearce EM; Sakamoto FH; Blakeley JO; Anderson RR; Plotkin SR;
Neurology; 2021 Aug; 97(7 Suppl 1):S32-S41. PubMed ID: 34230197
[TBL] [Abstract][Full Text] [Related]
17. RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in Cutaneous Neurofibroma Pathogenesis, Emerging Biological Insights.
Rhodes SD; McCormick F; Cagan RL; Bakker A; Staedtke V; Ly I; Steensma MR; Lee SY; Romo CG; Blakeley JO; Sarin KY
J Invest Dermatol; 2023 Aug; 143(8):1358-1368. PubMed ID: 37245145
[TBL] [Abstract][Full Text] [Related]
18. [Treatment and progress of cutaneous neurofibroma].
Zhu B; Wei C; Wang W; Gu B; Li Q; Wang Z
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2022 Sep; 36(9):1064-1071. PubMed ID: 36111466
[TBL] [Abstract][Full Text] [Related]
19. Head circumference and anthropometric changes and their relation to plexiform and skin neurofibromas in sporadic and familial neurofibromatosis 1 Brazilian adults: a cross-sectional study.
Basto DL; de Souza Vieira G; Andrade-Losso RM; Almeida PN; Riccardi VM; Rozza-de-Menezes RE; Cunha KS
Orphanet J Rare Dis; 2022 Sep; 17(1):341. PubMed ID: 36064430
[TBL] [Abstract][Full Text] [Related]
20. Activation of PLCγ/AKT/IκBα/p65 signaling increases inflammation in mast cells to promote growth of cutaneous neurofibroma.
Xu J; Zhang H; Li C; Du H; Shu M; Jia J
Life Sci; 2019 Dec; 239():117079. PubMed ID: 31756343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
